• EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57
  • EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57
  • Editorial Board

    Dec 1, 2023, 08:12
  • EPH252 A Systematic Review of the Global Burden of Endometriosis

    Dec 1, 2023, 00:00
  • EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario

    Dec 1, 2023, 00:00
  • EE486 Municipality Costs Due to COVID-19 Infections in Denmark: A Cost-of-Illness Study

    Dec 1, 2023, 00:00
  • EE421 Cost-Effectiveness of Empagliflozin in Adult Patients with Chronic Kidney Disease in the Netherlands

    Dec 1, 2023, 00:00
  • HTA190 The JCA Is Coming: Will the EU Band Together?

    Dec 1, 2023, 00:00
  • EE388 Cost of Illness for Advanced Hepatocellular Carcinoma (aHCC) in Ontario, Canada

    Dec 1, 2023, 00:00
  • EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German Dermatologic Cooperative Oncology Group

    Dec 1, 2023, 00:00
  • SA34 The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • EE171 Cost Offset and Budget Impact of Skytrofa for the Treatment of Pediatric Growth Hormone Deficiency: A US Payer’s Perspective

    Dec 1, 2023, 00:00
  • EPH158 Impact of Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) Related Cancers Elimination on Treatment Patterns in the United Kingdom (HELP-UK)

    Dec 1, 2023, 00:00
  • HTA209 A Review of the Differences Between the New EMA-EUnetHTA Joint Scientific Consultation Versus the Previous Ema-HTA Parallel Scientific Consultation

    Dec 1, 2023, 00:00
  • EPH230 Systematic Literature Review on the Clinical and Economic Burdens of Antimicrobial Resistance in the Japanese Population

    Dec 1, 2023, 00:00
  • OP4 Scientific Communication Plans in Health Economics and Real-World Evidence

    Dec 1, 2023, 00:00
  • P42 Enhancing the Understanding of Phenotypic Outcomes in Sickle Cell Disease (SCD) Through a Comparison Between Data Collected Through App-Based Home-Reported Outcomes (HROs) Versus Qualitative Methodologies

    Dec 1, 2023, 00:00
  • HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement

    Dec 1, 2023, 00:00
  • PCR144 Impact of Oral Corticosteroid Use on Health-Related Quality of Life: Analysis of EQ-5D Data from Navigator

    Dec 1, 2023, 00:00
  • HTA43 Exploring the Link Between Institutional Country-Level Differences and Consideration of Additional Value Elements in HTAs: Results From a Pragmatic Review

    Dec 1, 2023, 00:00
  • RWD130 Healthcare Resource Utilization for Pediatric and Adolescent Duchenne Muscular Dystrophy Patients: Analysis of Real-World Data

    Dec 1, 2023, 00:00
  • PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

    Dec 1, 2023, 00:00
  • HTA12 Focus on Two Years of Economic Opinions on Solid Cancers: What Are the Specific Features?

    Dec 1, 2023, 00:00
  • MT20 Assessing the Economic Impact of Standardization of Operating Room Workflows Through a Digital Solution

    Dec 1, 2023, 00:00
  • HPR62 Impact of GKV Financial Stabilization Act on Drug Pricing in Germany – Early Experiences of the Reform

    Dec 1, 2023, 00:00
  • MSR61 Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project

    Dec 1, 2023, 00:00
  • HPR217 Stakeholders' Perspectives on the Unmet Medical Need Concept: A EU Pharmaceutical Strategy Survey Analysis

    Dec 1, 2023, 00:00
  • P54 Patient-Reported Health Economic Outcomes for Low-Value Medications in Patients Living with Dementia

    Dec 1, 2023, 00:00
  • HTA293 Challenges and Opportunities in Implementing the EUnetHTA21 Methodological Guidelines in the Context of EU HTA Regulation: Perspectives From Different Stakeholders on Different Markets (France, Italy, and Poland)

    Dec 1, 2023, 00:00
  • RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

    Dec 1, 2023, 00:00
  • EPH254 Changes in Asthma-Related Healthcare Resource Use in Asthma Patients in the United States During the COVID-19 Pandemic

    Dec 1, 2023, 00:00
  • EE537 How Good Are Cost-Effectiveness Model Predictions When Compared to Longer Follow-up Data? An Example of Nivolumab Studies in the First-Line Gastro-Oesophageal Setting

    Dec 1, 2023, 00:00
  • EE634 Resource Utilization and Costs Related to Inflammatory Bowel Disease: A Longitudinal Analysis Based on Routine Data from Two German Statutory Health Insurance Providers

    Dec 1, 2023, 00:00
  • RWD84 Building Federated Data Networks With Common Data Models to Generate Insights Through Real-World Evidence Observational Studies in Oncology

    Dec 1, 2023, 00:00
  • HTA47 An Overview of the Challenges in the HTA of Interventions Involving Healthcare Reorganisation

    Dec 1, 2023, 00:00
  • EE503 Impact of Managing Multiple Sclerosis Patients in a Private Health Insurance Company in Brazil

    Dec 1, 2023, 00:00
  • EE462 Same Day Discharge after Percutaneous Transluminal Coronary Angioplasty (PTCA): Is It Cost Saving?

    Dec 1, 2023, 00:00
  • EE729 Early Intervention With Biosimilars Compared With Leflunomide in Established Rheumatoid Arthritis: A Cost-Effectiveness Analysis in Hong Kong

    Dec 1, 2023, 00:00
  • HSD129 Does Digital Healthcare Improve the Utilization of Public Hospitals in the Emirate of Dubai?

    Dec 1, 2023, 00:00
  • EE208 A Total Cost of Care Analysis of Immune-Oncology (IO) Treatments for Unresectable Hepatocellular Carcinoma (uHCC): A Canadian Payer Perspective

    Dec 1, 2023, 00:00
  • HPR83 The Price Is Right or Is It? Navigating the Inflation Reduction Act (IRA) With Payer Perspectives on Evidence Needs, Fair Market Pricing, and Patient Access Implications

    Dec 1, 2023, 00:00
  • EE180 Comparing the Environmental Costs of Differentiated Service Delivery of Antiretroviral Therapy for People Living with HIV in Rural South Africa

    Dec 1, 2023, 00:00
  • SA29 Evaluating the Adherence to ISPOR Guidelines in Globally Published Budget Impact Analyses of New Drugs: A Targeted Literature Review

    Dec 1, 2023, 00:00
  • EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel in 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States Utilizing Real-World Evidence of Chimeric Antigen Receptor T-Cell Therapies

    Dec 1, 2023, 00:00
  • MT14 Inequity in Access to Breast Reconstruction Techniques in Belgian Health System: Is it Justified?

    Dec 1, 2023, 00:00
  • EE169 Novel Post-Processing Methods for Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Heat Map and Density-Based Clustering

    Dec 1, 2023, 00:00
  • HSD97 Exploring European Expert Opinion to Ensure Provision Outcomes in a Post-COVID World

    Dec 1, 2023, 00:00
  • HSD2 Using Automated Data Extraction Methods to Understand the Evolution of Insulin Prescribing in the UK between 2021 and 2022

    Dec 1, 2023, 00:00
  • HTA256 Identifying Current ATMP Market Access Challenges and Strategies in France, Germany, Italy, and Spain

    Dec 1, 2023, 00:00
  • HTA160 Development of a Web Application for Self-Assessment and Monitoring of Colorectal Surgery Outcome Indicators in the ESCA Study

    Dec 1, 2023, 00:00
  • SA47 Exploring the Use of Health Technology Assessment in Uganda’s Health Policy and Financing Decision-Making Processes

    Dec 1, 2023, 00:00
  • CO113 Impact of Clinical Pharmacist-Led Intervention on Somatic Cell Therapy Medicinal Product Circuit in Portugal

    Dec 1, 2023, 00:00
  • HTA11 Drivers of Positive Health Technology Assessment Outcomes for Oncology Drugs in Three Global Markets

    Dec 1, 2023, 00:00
  • EPH169 Examination of the Quality of Life of Patients Underwent Ischemic Stroke and Treated With Intravenous Thrombolytic and Mechanical Thrombectomy Recanalization Intervention

    Dec 1, 2023, 00:00
  • HTA122 How Has NICE's Severity Modifier Been Implemented?

    Dec 1, 2023, 00:00
  • MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials

    Dec 1, 2023, 00:00
  • OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)

    Dec 1, 2023, 00:00
  • CO112 Clinical Characteristics and Quality of Life of Thai Moderate to Severe Psoriasis Patients Before Initiating Secukinumab: An Interim Analysis from Prompt Study

    Dec 1, 2023, 00:00
  • HSD114 Treatment Patterns and Adverse Events (AEs) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)

    Dec 1, 2023, 00:00
  • EE665 Evaluation of Resource Use and Costs of Pertuzumab and Trastuzumab Formulations in HER2- Positive Breast Cancer

    Dec 1, 2023, 00:00
  • EE244 Healthcare Resource Utilization and Costs in Patients with Alagille Syndrome Using Population-Based Healthcare Data from South Korea

    Dec 1, 2023, 00:00
  • EE276 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Prurigo Nodularis in Adult Patients in Italy

    Dec 1, 2023, 00:00
  • HTA288 How Wide Ranging Is the Implementation of HTA and Cost-Effectiveness Assessment (CEA) in Major Healthcare Markets

    Dec 1, 2023, 00:00
  • PCR212 A Novel Approach to Capturing Real-World Reasons Behind Use and Satisfaction of NVX-CoV2373 Booster Use Among German Adults: Direct-to-Patient Enrollment

    Dec 1, 2023, 00:00
  • HPR195 Market Access Implications of Early Access to Medicines Scheme in the UK

    Dec 1, 2023, 00:00
  • MT60 Digital Health Applications (DIGA) in Germany—An Observation of Clinical Evidence Submissions

    Dec 1, 2023, 00:00
  • HPR182 Oncology Combination Market Access Conundrum in Europe

    Dec 1, 2023, 00:00
  • EE193 Evaluating Clinical Benefits of Vertebral Body Stenting in Treating Osteoporotic Vertebral Compression Fracture: A Physician Survey

    Dec 1, 2023, 00:00
  • HTA203 Identification and Comparison of HTA Tools Suitable for Low- and Middle-Income Countries

    Dec 1, 2023, 00:00
  • EPH50 Impact of Dispensed Medication on Mean Age of Death: A Brazilian Public Health System Study

    Dec 1, 2023, 00:00
  • MT52 Economic and Organizational Advantages of Mrgfus for the Treatment of Essential Tremor in Italy

    Dec 1, 2023, 00:00
  • EE256 Economic Burden of Geographic Atrophy: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • RWD103 NVX-CoV2373 Patient Characteristics in Germany: Real-World Retrospective Database Study Shows Most Vaccine Recipients Were Among the High Risk Category

    Dec 1, 2023, 00:00
  • HSD90 Beyond the Hospital Walls: Hospital at Home Programs for Cancer Patients Worldwide and the Road to Implementation in Greece

    Dec 1, 2023, 00:00
  • EE225 Exploring the Value of Country-Specific Cost-Effectiveness Models in Early Stages of Drug Development

    Dec 1, 2023, 00:00
  • EE328 Healthcare Costs in Patients With Hepatic Encephalopathy Receiving Rifaximin-α Treatment in the IMPRESS-II Study

    Dec 1, 2023, 00:00
  • EPH270 Impacts of Different SARS-CoV-2 Variants on Hospital Usage and Performance in the United Arab Emirates: A Comparison Among Alpha, Delta, and Omicron

    Dec 1, 2023, 00:00
  • EE350 Budget Impact of Memantine for Alzheimer's Patient in the United States

    Dec 1, 2023, 00:00
  • HPR173 Supply-Side Stakeholders’ Opinions and Perspectives on the Development of Medical Tourism in the Region of Thessaly, Greece

    Dec 1, 2023, 00:00
  • OP20 Carer Health-Related Quality of Life in Health Technology Assessments: Process Recommendations for Determining Relevance, Data Collection, and Inclusion in Health-Economic Models

    Dec 1, 2023, 00:00
  • CO159 A Bayesian Network Meta-Analysis (NMA) for Evaluating the Relative Efficacy of Dual Therapy Combinations of Dapagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2023, 00:00
  • SA64 Systematic Literature Review of Measurement and Valuation Methods for Societal Costs: A Focus on Cost-Effectiveness Analyses of Three Types of Disease Potentially Associated with High Spillover Effects

    Dec 1, 2023, 00:00
  • EE284 A Qualitative Primary Market Research Study on the Economic Investment of Scaling up Bariatric Surgery Capacity Within the NHS

    Dec 1, 2023, 00:00
  • EE414 Incremental Costs of Abrocitinib Compared to Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Denmark

    Dec 1, 2023, 00:00
  • HTA274 Similarities and Differences in Health Technology Assessment (HTA) Bodies Considerations for Decision-Making: Use of Patient Preference Studies

    Dec 1, 2023, 00:00
  • PCR130 Factors Associated With Adjuvant Treatment Options in Resected Stage III Melanoma, From a Patient and Physician Perspective: Preference Assessment Using the Discrete Choice Experiment Method (Pamela Study)

    Dec 1, 2023, 00:00
  • HTA99 Expert Validation on Proposed Framework for Differentiated HTA Criteria for Rare Disease Drugs in Brazil

    Dec 1, 2023, 00:00
  • SA24 Can an Integrated Systematic Literature Review (SLR) Database Improve the Speed of Title and Abstract (TIAB) Review? A Case Study Using Multiple Myeloma (MM) Projects in Interventional and Real-World Evidence (RWE) Evidence

    Dec 1, 2023, 00:00
  • EE231 Model-Based Assessment of the Costs and Benefits of Directly Mailing Self-Sampling HPV Kits to Non-Participants in Cervical Screening in the Czech Republic

    Dec 1, 2023, 00:00
  • MT35 The Impact of Patient Engagement with a Digital Diabetes Solution on All-Cause Healthcare Resource Utilization Rates and Charges

    Dec 1, 2023, 00:00
  • EPH221 Age, Sex, and Comorbidity Differences Between Patients with Mild and Severe Aortic Stenosis in German Cardiology Practices

    Dec 1, 2023, 00:00
  • EPH265 Updated Estimations of the HPV Vaccination Deficit Among Girls in Gree Early Signs of Recovery?

    Dec 1, 2023, 00:00
  • CO92 Clinician-Reported Outcome Measure for Palonosetron Versus Standard of Care in Chemotherapy-Induced Nausea and Vomiting in Egypt

    Dec 1, 2023, 00:00
  • EPH155 Burden of Clinical Syndromes Associated with Pneumococcal Disease in Peru: A 2019 Perspective

    Dec 1, 2023, 00:00
  • HPR185 The Influence of Value Frameworks on Payer and Oncologist Decision-Making in the United States (US)

    Dec 1, 2023, 00:00
  • SA17 Application of CPRD Data in NICE Submissions: Model Inputs for Functional Health States

    Dec 1, 2023, 00:00
  • RWD73 Exposing the True Economic Impact of Stroke: A Comparative Analysis of Time-Driven Activity-Based Costing and Reimbursement Methods in Brazil

    Dec 1, 2023, 00:00
  • EE481 Cost-Effectiveness Analysis of Upadacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in Greece

    Dec 1, 2023, 00:00
  • CO147 Impact of COVID-19 on Patients With Asthma in US Routine Care

    Dec 1, 2023, 00:00
  • EE174 Evaluating the Budget Impact of the Co-Existence of Oral and Injectable Forms of Semaglutide in the Saudi Public Healthcare System

    Dec 1, 2023, 00:00
  • PCR12 Construct Validity of a New Migraine Satisfaction with Treatment Questionnaire

    Dec 1, 2023, 00:00
  • HSD31 Impact and Management of Comorbidities in People With Obesity: A Multinational Survey

    Dec 1, 2023, 00:00
  • HPR60 Voluntary Scheme for Branded Medicines Pricing and Access vs Statutory Scheme: A Case of Six vs Half a Dozen?

    Dec 1, 2023, 00:00
  • RWD154 Using Real World Evidence from the UK MS Register to Support Optimal Healthcare Decision Making

    Dec 1, 2023, 00:00
  • P16 What Trade-Offs Are Women Willing to Make When Choosing Between Potential Treatments for Moderate-to-Severe Vasomotor Symptoms Due to Menopause?

    Dec 1, 2023, 00:00
  • MSR90 Is the Current Chatgpt Able to Gatherarticles for HEOR Literature Review

    Dec 1, 2023, 00:00
  • CO117 Prognostic Factors and Surrogate Endpoints in Obstructive Hypertrophic Cardiomyopathy: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • EPH274 Health-Related Quality of Life in a Large Cohort of Adult Patients With Sickle Cell Disease in France (The DREPAtient Study)

    Dec 1, 2023, 00:00
  • RWD30 Applying Transportability Methods to Real-World Data: A Scoping Review

    Dec 1, 2023, 00:00
  • RWD60 APNEE Study: A Challenge to Identify Patients Treated with Dupilumab for Chronic Rhinosinusitis with Nasal Polyps (CRSWNP) in Real-Life Settings in France

    Dec 1, 2023, 00:00
  • EE92 Introduction to the Duchenne Muscular Dystrophy Burden-of-Illness Study Expanded (US AND SPAIN)

    Dec 1, 2023, 00:00
  • EE685 Screen-and-Treat Cervical Cancer Screening Strategy Using High-Risk HPV Testing: Early Evaluation for Uganda

    Dec 1, 2023, 00:00
  • HTA318 Delays in NICE Highly Special Technology (HST) Appraisal for Medicines That Treat Ultra-Orphan Conditions

    Dec 1, 2023, 00:00
  • SA49 Capturing Real-World Evidence Alongside Trial Evidence in HTA-Specified Systematic Literature Review: Optimizing Search Strategies across the Totality of Evidence Required

    Dec 1, 2023, 00:00
  • EE728 Examining Hospital-Onset Urinary Tract Infection (HO-UTI) in Male Patients – Modeling the Economic Impact of Utilizing External Male Wicking Catheters (EMWCS)

    Dec 1, 2023, 00:00
  • RWD11 Real-World Persistence on Cladribine Tablets of Patients with RMS over 4 Years Based on Claims Data

    Dec 1, 2023, 00:00
  • MSR115 Using Machine Learning to Assess Potential Cases of Transthyretin Cardiac Amyloidosis in Brazil: A Retrospective Database Approach

    Dec 1, 2023, 00:00
  • EE648 Systematic Review of the Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy

    Dec 1, 2023, 00:00
  • HPR54 Policy Approaches to the Regulation and Reimbursement of Pediatric Medicines: Comparing Canadian, European, and UK Health Systems

    Dec 1, 2023, 00:00
  • EE163 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for Primary Prevention in China

    Dec 1, 2023, 00:00
  • EE3 Micro-Costing Analysis for the Treatment of Atrial Fibrillation: An Economic Evaluation

    Dec 1, 2023, 00:00
  • HTA18 Challenges of Identifying Health Utility Data for Patients With Penta-Refractory Multiple Myeloma to Inform HTA Reimbursement Discussion for Newer Treatment Options

    Dec 1, 2023, 00:00
  • Care Pathway Analysis to Inform the Earliest Stages of Technology Development: Scoping Oncological Indications in Need of Innovation

    Dec 1, 2023, 00:00
  • HTA315 Implications for Rare Diseases: NICE Guidance and Outcomes on Implementing Bayesian Borrowing Approaches for External Control Data

    Dec 1, 2023, 00:00
  • EE30 Framework Concepts for Economic Evaluation of New Antibiotics

    Dec 1, 2023, 00:00
  • PCR52 Use of Patient Reported Outcomes in Key Trials Supporting Marketing Authorisation: 5-Year Analysis of Company Evidence Submitted for National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA)

    Dec 1, 2023, 00:00
  • CO190 Cannabis-Based Formulations: Clinical and Economic Results Promising Savings and Sustainability

    Dec 1, 2023, 00:00
  • HTA75 Evaluation of the Clinical and Economic Effectiveness of Continuous Glucose Monitoring in Adults With Type 1 Diabetes Mellitus in the Healthcare System of the Republic of Kazakhstan

    Dec 1, 2023, 00:00
  • EE617 A Systematic Review of Economic Evaluations of Balloons and Stents for Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

    Dec 1, 2023, 00:00
  • EE439 Public Health Impact of the Pediatric Immunization Program in the Netherlands

    Dec 1, 2023, 00:00
  • RWD139 Exploring Respiratory Syncytial Virus and Influenza Trends Pre- and Post-COVID-19 in the US and EU-5 Countries

    Dec 1, 2023, 00:00
  • EPH63 Obesity Related Complications: Can America Be Europe's Canary in the Coal Mine?

    Dec 1, 2023, 00:00
  • HPR82 The Comparative Analysis of Accelerated Coverage Pathways for Innovation (ACPI) for Digital Technologies: In the Landscape of Germany, France, and the United Kingdom

    Dec 1, 2023, 00:00
  • RWD156 Real-World Progression Patterns in First and Second Lines of Systemic Therapy for Endometrial Cancer

    Dec 1, 2023, 00:00
  • CO110 Systematic Literature Review and Network Meta-Analysis to Assess the Comparative Efficacy of Topical Fixed-Dose Combinations for Moderate to Severe Acne Vulgaris as Measured By Lesion Counts

    Dec 1, 2023, 00:00
  • PT18 Novel Approaches to Unify Multi-State Transition Modelling Methods and Develop a Synthetic English Population to Support Health Economic Evaluation Studies

    Dec 1, 2023, 00:00
  • HPR162 Pharmaceutical Rebates – An Anglo-French Comparison

    Dec 1, 2023, 00:00
  • EPH19 Mental Health Disparities for Young Adults with Arrest Histories in the United States

    Dec 1, 2023, 00:00
  • P32 Implementation of Early Access Reform in France and Access to Innovation: Impact in Terms of Number of Drugs, Patients Treated, and Cost

    Dec 1, 2023, 00:00
  • RWD67 The Health Resource Utilization and Medical Costs of Cataract Surgery in Pediatric Patients: A National Population-Based Study in a Korea

    Dec 1, 2023, 00:00
  • HPR139 Access to Targeted Therapies for Solid Tumors in Turkey

    Dec 1, 2023, 00:00
  • EPH207 The Adverse Event Profiles of Modafinil in Approved Indications and Off-Label Use for Major Depressive Disorder: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • EPH250 Clinical Characteristics of Generalized Pustular Psoriasis Flares in the Real-World Setting

    Dec 1, 2023, 00:00
  • EE405 Cost-Effectiveness of Single-Inhaler Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium vs Other Open or Single-Inhaler Triple Therapies in Adult Patients with Uncontrolled Asthma in England

    Dec 1, 2023, 00:00
  • EE52 Evaluation of the Economic Impact of Initial Diagnostic Modality Selection for Patients Suspected of Having Colorectal Cancer Liver Metastases or Hepatocellular Carcinoma in the UK

    Dec 1, 2023, 00:00
  • HTA278 Risky Business: How Does Risk of Study Bias Impact Health Technology Assessment Submissions?

    Dec 1, 2023, 00:00
  • P48 New NICE Proportionate Approaches: Are They Any Faster or More Successful?

    Dec 1, 2023, 00:00
  • EE351 Using Social Return on Investment to Capture the Broader Impact of Medicines: Advanced Parkinson's Disease Example

    Dec 1, 2023, 00:00
  • SA68 Consistency Between Network Meta-Analysis and Real-Word Data Analysis: Comparison of Changes in Hemoglobin A1c Levels After Treatment with Metformin Vs the Other Oral Antidiabetics in Japanese Patients with Type 2 Diabetes

    Dec 1, 2023, 00:00
  • MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial

    Dec 1, 2023, 00:00
  • EPH46 Validation of Dynamic Transmission Model for Varicella Immunization Program in Germany

    Dec 1, 2023, 00:00
  • P12 Screen-Detected Breast Cancers Have Improved 5-Year Disease Free Interval Compared to Interval and Non-Screen-Related Breast Cancer, Taking Lead Time into Account

    Dec 1, 2023, 00:00
  • HSD4 Institutional and Geographical Variation in Discharge Destination Among Admission Avoidance Municipal Inpatient Acute Care Units in Norway

    Dec 1, 2023, 00:00
  • SA27 Menopause: More Than Just Vasomotor Symptoms

    Dec 1, 2023, 00:00
  • HTA255 First-in-Class Drugs in HTA: Blunder or Bliss?

    Dec 1, 2023, 00:00
  • PCR245 Stakeholder Engagement and Expert Consultation on the EuroQol Toddler and Infant Populations (EQ-TIPS) Measure of Health-Related Quality of Life (HRQoL)

    Dec 1, 2023, 00:00
  • HSD35 Treatment and Dosage Patterns of Oral Corticosteroids Among Patients With Myasthenia Gravis: A Tale of Two Countries

    Dec 1, 2023, 00:00
  • EE60 An Overview of Systematic Reviews of Economic Evaluations on Cancer Screening: Landscape, Quality, and Recommendations

    Dec 1, 2023, 00:00
  • EE168 A Markov Model to Determine the Cost-Effectiveness of a Multi-Targeting Bacterial Gene Therapy (AUP-16) at Healing a Diabetic Foot Ulcer When Compared to the Current Standard of Care

    Dec 1, 2023, 00:00
  • EE404 The Economic Burden That Respiratory Syncytial Virus (RSV) Imposes on Irish Hospitals

    Dec 1, 2023, 00:00
  • HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review

    Dec 1, 2023, 00:00
  • HSD36 Impact of Non-Medical Factors on Patterns of Treatment in Patients With Cancer: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • PCR273 Perceptions, Attitudes, and Satisfaction with Private Pharmacies in Gree Results from a Nationwide Survey

    Dec 1, 2023, 00:00
  • EE756 Real World Evidence (RWE) Evaluation of Cost Savings through Continuous Vital Sign Monitoring in the Medical-Surgical Ward: A National Health Service (NHS) Experience

    Dec 1, 2023, 00:00
  • EE676 Cost Considerations: Exploring the Economic Implications of Choosing SC or IV Administration

    Dec 1, 2023, 00:00
  • EPH21 An Assessment of Validated Algorithms for Identifying Multiple Sclerosis Cases, Subtypes, and Relapses in Real-World Databases: A Systematic Review

    Dec 1, 2023, 00:00
  • EPH201 Epidemiology of Actinic Keratosis in Fran A General Population Survey (REAKT STUDY)

    Dec 1, 2023, 00:00
  • CO22 Healthcare Resource Utilization (HCRU), Effectiveness and Safety of Trifluridine/Tipiracil in Treatment of Refractory Metastatic Colorectal Cancer in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2023, 00:00
  • EPH243 Overview of Lung Cancer Screening Studies in France and Bordering Countries

    Dec 1, 2023, 00:00
  • HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

    Dec 1, 2023, 00:00
  • RWD21 Impact of Haemophilia Severity on Healthcare Resource Usage: Results from a Multinational Real-World Survey

    Dec 1, 2023, 00:00
  • EPH209 Incidence Rates for an Extensive List of Adverse Events of Special Interest in the Pre-COVID-19 and Active COVID-19 Eras: A Comprehensive Source for Representative Historical Background Rates in the US General Population

    Dec 1, 2023, 00:00
  • EE696 Economic and Clinical Burden Associated with Respiratory Syncytial Virus (RSV) and Expected Impact of Universal Immunization with Nirsevimab Among All Infants in Their First Rsv Season Against Standard of Care in Italy

    Dec 1, 2023, 00:00
  • HSD130 Development of a Risk-Adjusted in-Hospital Complication Rate (RAICR) Using Machine Learning Methods

    Dec 1, 2023, 00:00
  • SA12 Discrepancy of Health State Utility Values in Cost-Utility Analyses of Interventions Against Infectious Diseases in Older Adults

    Dec 1, 2023, 00:00
  • EE526 Health Benefits and Cost-Effectiveness Analysis of Early Cervical Cancer Diagnosis in Bulgaria

    Dec 1, 2023, 00:00
  • EE248 Evolution in Price Levels of Orphan Medicinal Products (OMP): Looking Back at the Past Decade

    Dec 1, 2023, 00:00
  • EPH44 Temporary Soft Tissue Coverage in Burn Patients - Which Materials Are Used - and By Whom? Analysis of German Billing Data

    Dec 1, 2023, 00:00
  • HTA97 Exploring the Value of RWD Collected From Early Access Programs to Support HTA Decision-Making

    Dec 1, 2023, 00:00
  • EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

    Dec 1, 2023, 00:00
  • SA42 Project SATURN – A Real-World Evidence and Data Collaboration With Existing European Datasets in Osteogenesis Imperfecta to Support Future Therapies

    Dec 1, 2023, 00:00
  • PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study

    Dec 1, 2023, 00:00
  • HTA253 Analysis of HTA Assessments, Usage, and Reimbursement of Newly Introduced Outpatient Drugs in the Netherlands Between 2017 and 2021 – A Secondary Data Analysis

    Dec 1, 2023, 00:00
  • EE368 Would Initiating Colorectal Cancer Screening from Age of 45 Be Cost-Effective in Germany? An Individual-Level Simulation Analysis

    Dec 1, 2023, 00:00
  • SA72 Current Practices for the Selection of Effect Modifiers and Confounders in Population-Adjusted Indirect Comparisons (PAIC): A Review of Technology Appraisals (TA)

    Dec 1, 2023, 00:00
  • HPR207 Moving to Outcomes-Based Agreements in Algeria: Sharing Experiences Between Saudi Arabia and Algeria

    Dec 1, 2023, 00:00
  • HPR140 Quantifying the Impact of Novel Anti-Cancer Therapies on Health Inequalities in Survival Based on Kaplan-Meier Curves

    Dec 1, 2023, 00:00
  • HSD77 The Impact of the COVID-19 Pandemic on Patient Flow and Key Performance Indicators (KPIS) of Hippocration General Hospital of Athens

    Dec 1, 2023, 00:00
  • P22 Disrupting Health Economics: Automating Network Meta-Analyses With AI and Large Language Models

    Dec 1, 2023, 00:00
  • CO37 Inventory-Facilitated Goal Setting Interview Conducted by Disease Experts Yields a Broader Range of Goal Areas

    Dec 1, 2023, 00:00
  • EE90 Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Show Substantial Healthcare Resource Utilization

    Dec 1, 2023, 00:00
  • HTA53 Proportionally Quicker or Easier? International Comparison of NICE’s Proportionate Approach to Technology Appraisals (PATT) With Global Peers

    Dec 1, 2023, 00:00
  • MSR104 Deriving Caregiver Health Utilities from Patient Endpoints: A Predictive Modelling Approach Using Real-World Survey Data

    Dec 1, 2023, 00:00
  • EE107 Estimating EQ-5D Utilities From the Facial Vitiligo Area Scoring Index (F-VASI) in Vitiligo Patients Using a Mapping Algorithm Applied to 2 Pooled Randomized Controlled Trials

    Dec 1, 2023, 00:00
  • RWD97 Systematic Identification, Access, and Utility Mapping of Asia Pacific Real-World Data Sources for Rare and Non-Rare Retinal Diseases

    Dec 1, 2023, 00:00
  • P46 Drivers of Health Technology Assessment Methods and Process Reforms: An International Comparison of Real World Evidence, Patient Involvement and Discounting

    Dec 1, 2023, 00:00
  • HPR17 Exploring Heterogeneity in Biosimilars Dynamics in Italy: Results From Three Chronic Therapeutic Areas

    Dec 1, 2023, 00:00
  • CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity

    Dec 1, 2023, 00:00
  • CO171 Associations of Sex and Race with Relative Efficacy in Clinical Trials

    Dec 1, 2023, 00:00
  • SA36 Safety, Efficacy, Quality of Life, and Treatment Dynamic of Conventional Therapies for Adults and Adolescents Suffering From Eosinophilic Esophagitis, a Type 2 Inflammatory Disease: Qualitative and Quantitative Synthesis

    Dec 1, 2023, 00:00
  • CO111 Clinical Efficacy and Safety of Interventions for Adult Patients With Moderately Severe to Severe Hemophilia B: A Systematic Review

    Dec 1, 2023, 00:00
  • HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study

    Dec 1, 2023, 00:00
  • PCR275 An Interpretive Phenomenological Analysis of Financial Toxicity in Indonesian Cancer Patients

    Dec 1, 2023, 00:00
  • CO142 A Retrospective Study Characterizing Age at Key Clinical Disease Indicators Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00
  • EPH92 The Development of an Interactive Visual Tool to Communicate the Burden of Atopic Dermatitis in Finland

    Dec 1, 2023, 00:00
  • PCR253 The Burden of Persistent Cough in Idiopathic Pulmonary Fibrosis (IPF) and Other Interstitial Lung Diseases (ILD): A Systematic Evidence Synthesis

    Dec 1, 2023, 00:00
  • HTA327 Acceptance of Real-World Evidence As Comparative Efficacy in Lieu of Trial Eviden A Review of Past NICE Appraisals in Oncology

    Dec 1, 2023, 00:00
  • MSR67 Art or Science? Selecting Utility Evidence for Decision-Analytic Models Containing Multiple Health-States

    Dec 1, 2023, 00:00
  • CO123 Long COVID Symptom Diary: Development of a PRO Instrument to Support Drug Development and Regulatory Submissions in Europe

    Dec 1, 2023, 00:00
  • EE4 Cost-Effectiveness of Andexanet Alfa Versus Prothrombin Complex Concentrate Is Likely for the Treatment of Factor Xa Inhibitor–Related Major Bleeds in the Netherlands

    Dec 1, 2023, 00:00
  • RWD39 Comparative Effectiveness and Health Resource Utilization of Xuesaitong Soft Capsule in Patients with Stroke of Secondary Prevention in China: A Retrospective Cohort Study

    Dec 1, 2023, 00:00
  • PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease

    Dec 1, 2023, 00:00
  • EE94 Current State of Health Economic Models in Hereditary Angioedema

    Dec 1, 2023, 00:00
  • RWD9 Identifying Predictors of Response Following Discontinuation of JAKi Therapy in Patients with Rheumatoid Arthritis

    Dec 1, 2023, 00:00
  • HTA346 The Use of Real-World Evidence in Health Technology Assessment Decisions in Sweden and the UK: A Natural Language Processing (NLP) Approach

    Dec 1, 2023, 00:00
  • EPH122 Global Burden of Disease Study on Chikungunya: Estimating Dalys and Cost Burden

    Dec 1, 2023, 00:00
  • MT48 Digital Health Technologies: Challenges in Evaluating Same ‘Class’ of Technologies

    Dec 1, 2023, 00:00
  • EPH198 Annual Health Insurence Treatment Cost of Polycystic Ovary Sindrome Based on Routinely Collected Financing Data Between 2010-2019

    Dec 1, 2023, 00:00
  • EE118 Cost Incurred Post-Kidney Transplant: A Systematic Review

    Dec 1, 2023, 00:00
  • SA74 A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

    Dec 1, 2023, 00:00
  • HPR209 Criteria for Decision-Making on Drug Financing in Spain: How Do We Measure Them and What Relevance Does Each One Have?

    Dec 1, 2023, 00:00
  • EE521 Economic Evaluation of Trastuzumab Deruxtecan for HER2+ Advanced Gastric Cancer Patients

    Dec 1, 2023, 00:00
  • MSR74 The Use of Matching-Adjusted Indirect Comparison for Oncology Submissions in NICE

    Dec 1, 2023, 00:00
  • HPR65 Pricing and Reimbursement Mechanisms for Advanced Therapeutic Medicinal Products in 20 Countries

    Dec 1, 2023, 00:00
  • EE608 The Use of Vignette Studies to Estimate Health-State Preference in Sweden and Norway

    Dec 1, 2023, 00:00
  • EE396 Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • RWD101 Intravitreal Therapies and Their Patterns of Use in Lombardy Region

    Dec 1, 2023, 00:00
  • EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa

    Dec 1, 2023, 00:00
  • PCR215 Usability Testing of a Non-Consumer Smartphone Device for ePRO Data Collection

    Dec 1, 2023, 00:00
  • OP15 Analysis of the Multidisciplinary Approach for the Management of Patients Affected by Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia in Italy

    Dec 1, 2023, 00:00
  • RWD80 Labor Impact in Patients with Rheumatoid Arthritis (RA) Treated with Advanced Therapies

    Dec 1, 2023, 00:00
  • MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study

    Dec 1, 2023, 00:00
  • MT46 Implementation of Cost-Consequences Analysis As an Economic Evaluation Method for Artificial Intelligent (AI) Medical and Digital Technologies. the Case of Hosmartai (HORIZON 2020 FUNDED)

    Dec 1, 2023, 00:00
  • EE730 Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics in Eosinophilic-Associated Diseases

    Dec 1, 2023, 00:00
  • EPH59 An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy

    Dec 1, 2023, 00:00
  • EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective

    Dec 1, 2023, 00:00
  • RWD113 Switching to TNFi Versus Non-TNFi Biologics in Ulcerative Colitis Patients: Real-World Outcomes from a German Claims Data Analysis

    Dec 1, 2023, 00:00
  • CO73 Overview of COA Measures in SLE Clinical Trials and Label Claims

    Dec 1, 2023, 00:00
  • HPR201 Lessons from the COVID-19 Vaccines Taskforce

    Dec 1, 2023, 00:00
  • EE354 Value for Money: Evaluating the Economic Benefit of a Hypothetical Disease Modifying Therapy for Alzheimer's Disease From Canadian Payer and Societal Perspectives

    Dec 1, 2023, 00:00
  • OP12 Adherence to Intravenous to Oral Switching Criteria in a Tertiary Governmental Hospital in Riyadh, Saudi Arabia

    Dec 1, 2023, 00:00
  • EE114 Reductions in Travel Time and CO2 Emissions Arising From Patient Transportation to Hospitals in Ireland for Treatment With Intravenous Iron: An Analysis Comparing Ferric Derisomaltose With Ferric Carboxymaltose

    Dec 1, 2023, 00:00
  • HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

    Dec 1, 2023, 00:00
  • EPH237 Incidence and Risk Factors for Psychiatric Disorders Across Different Health Insurance Systems in Japan

    Dec 1, 2023, 00:00
  • PCR20 Preferences for Cancer Treatments: A Discrete-Choice Experiment with Adult Patients with Cancer in Europe

    Dec 1, 2023, 00:00
  • EE717 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France

    Dec 1, 2023, 00:00
  • HTA359 Market Access of ATMPs in Fran Challenges and Opportunities

    Dec 1, 2023, 00:00
  • EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy

    Dec 1, 2023, 00:00
  • EE286 Cost Effectiveness and Public Health Impact of Implementing Gender-Neutral Vaccination with the 9-Valent Human Papillomavirus Vaccine in Turkiye

    Dec 1, 2023, 00:00
  • HPR212 The Use of Managed Entry Agreements (MEAs) for Accessing Innovative Health Technologies

    Dec 1, 2023, 00:00
  • EPH263 Algorithmic Public Health? The Path Towards AI-Assisted Health Promotion

    Dec 1, 2023, 00:00
  • EE465 Sacubitril/Valsartan Vs Enalapril Use in the Outpatient Facilities Setting in Spain

    Dec 1, 2023, 00:00
  • HTA331 Health Technology Assessment of Point-of-Care Diagnostics for Antimicrobial Resistance; Perspectives and Recommendations from an Expert Advisory Panel

    Dec 1, 2023, 00:00
  • CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions

    Dec 1, 2023, 00:00
  • EE40 Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

    Dec 1, 2023, 00:00
  • HTA322 Modelling Antifibrotic Therapies for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease: Learnings from NICE Submissions from the Past Decade

    Dec 1, 2023, 00:00
  • EE759 Willingness-To-Pay for a QALY: A New Approach to Estimate Cost-Effectiveness Threshold Applied to France

    Dec 1, 2023, 00:00
  • EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider?

    Dec 1, 2023, 00:00
  • HPR35 Modelling the Effects of Smoking on Healthy Life Expectancy (HLE) in England

    Dec 1, 2023, 00:00
  • EE546 Development of a Drug Price Index for Approved Cystic Fibrosis Treatments

    Dec 1, 2023, 00:00
  • HSD116 Actual Use in Real World Setting of Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma in EU5 Countries and in the US

    Dec 1, 2023, 00:00
  • HPR28 Health Technology Assessment of New Drugs in Spain: Understanding the Evaluators’ Evidence Needs

    Dec 1, 2023, 00:00
  • HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in Fran A National Study Based on the Comprehensive Inpatient Stays Database

    Dec 1, 2023, 00:00
  • EE241 Budget Impact of Making Emicizumab Available at the Community Pharmacy in Addition to the Hospital Pharmacy

    Dec 1, 2023, 00:00
  • RWD78 Hospitalization Costs for Patients with Acute Appendicitis: An Update Using Real-World Data from a Large Province in China

    Dec 1, 2023, 00:00
  • EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France

    Dec 1, 2023, 00:00
  • CO32 Validation of a Scoring Algorithm for the Clinician-Reported Outcome ”Prurigo Activity and Severity (PAS)’’ Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis

    Dec 1, 2023, 00:00
  • MSR36 Model Framework to Derive Prevalence Estimates of Hepatitis Delta Based on Migration Patterns

    Dec 1, 2023, 00:00
  • EE506 RNA Interference Therapies for hATTR Amyloidosis With Polyneuropathy: Differential Healthcare Resource Use and Direct and Indirect Cost Consequences Associated With Vutrisiran Versus Patisiran

    Dec 1, 2023, 00:00
  • EE684 Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review

    Dec 1, 2023, 00:00
  • Using Artificial Intelligence to Enhance Efficiency in Systematic Reviews and Meta-Analyses

    Dec 1, 2023, 00:00
  • HTA187 Advancing a Collaborative Value Assessment Framework for Next-Generation Sequencing/Comprehensive Genomic Profiling in Europe: Building on and Enhancing an Existing Framework – A Multi-Stakeholder Web-Delphi Approach

    Dec 1, 2023, 00:00
  • EPH128 Evaluation of the Effects of the COVID-19 Pandemic on Depression Among the Under 20-Year-Old Population in Japan, the US, and Germany Before and During the COVID-19 Pandemic: A Retrospective Observational Study Using Real-World Data

    Dec 1, 2023, 00:00
  • HPR52 Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action

    Dec 1, 2023, 00:00
  • PCR158 The Uniqueness and Overlap of the EQ-HWB and the EQ-5D-5L in Four Diseases, Healthy Subjects, and Caregivers

    Dec 1, 2023, 00:00
  • EE264 Cost-Effectiveness Analysis of Upadacitinib in Patients with Active Non-Radiographic Axial Spondyloarthritis in Greece

    Dec 1, 2023, 00:00
  • MSR48 Using Bayesian Methodology to Minimize Control Recruitment in Trials of Relapsed and Refractory (RR) Multiple Myeloma (MM) Through Incorporation of Prior Control Response Information Borrowed From Real-World Evidence

    Dec 1, 2023, 00:00
  • EE594 Comparison of the Clinical and Economic Impact of Two COVID-19 Vaccines in Immunocompromised Patients in France

    Dec 1, 2023, 00:00
  • RWD8 Study of the Mental Health of Pharmacists During Wartime in Ukraine

    Dec 1, 2023, 00:00
  • PCR70 Factors Associated with Taking Preventive Migraine Medicines: Results from Overcome (EU) Study

    Dec 1, 2023, 00:00
  • HPR34 Analysis of Public Health Insurance Expenditures in Turkiye By SGK between 2020-2021-2022

    Dec 1, 2023, 00:00
  • HTA290 Environmental Sustainability in HTA: Are HTA Bodies Applying Environmental Criteria in Their Decision-Making?

    Dec 1, 2023, 00:00
  • HSD99 Analysis of Evidence Information About Herbal Medicinal Products and Its Use for Postgraduate Pharmacy Trainings in Ukraine

    Dec 1, 2023, 00:00
  • CO134 Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model

    Dec 1, 2023, 00:00
  • EPH224 Temporal Trends of Percutaneous Transluminal Coronary Angioplasty Procedure and Mortality Rates in the Brazilian Public Healthcare: A Real World Data Analysis From 2014 to 2022

    Dec 1, 2023, 00:00
  • EPH154 Modeled Head-to-Head Comparison of Nirsevimab and Rsvpref Maternal Vaccine in the US

    Dec 1, 2023, 00:00
  • CO84 Characterization of Long-COVID Phenotypes and Associated Clinical Phenotypes in Administrative Claims Data

    Dec 1, 2023, 00:00
  • EE701 Cost-Effectiveness Analysis of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in China

    Dec 1, 2023, 00:00
  • EE110 Economic Analysis of Sugammadex for Neuromuscular Block Reversal for Laparoscopic Surgery from a Single Hospital System in China

    Dec 1, 2023, 00:00
  • EE36 Economic Burden of Adults Hospitalized with Respiratory Syncytial Virus Infection in Spain, 2016–2019

    Dec 1, 2023, 00:00
  • CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00
  • HSD21 Regional Differences in the Use of Ige Testing in Primary Care: The Case of Sweden

    Dec 1, 2023, 00:00
  • RWD34 Characterization and Trends of Non-Hypothesis Evaluating Treatment Effectiveness (Non-HETE) Studies

    Dec 1, 2023, 00:00
  • PCR201 Estimating the Respiratory Syncytial Virus (RSV) Health Utility Values for Older Adults and Their Caregivers in the Japanese Population: A Time Trade-Off (TTO) Study

    Dec 1, 2023, 00:00
  • EE158 Cost Effectiveness and Budget Impact of Patient Blood Management in a Turkish State Hospital

    Dec 1, 2023, 00:00
  • SA48 Comparative Effectiveness Based on Win Ratios: Do Conventional ITC Approaches Work?

    Dec 1, 2023, 00:00
  • HTA237 Treatment Effect Waning in Immuno-Oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence

    Dec 1, 2023, 00:00
  • EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years

    Dec 1, 2023, 00:00
  • HSD39 Treatment Pathway and Unmet Needs of Mantle Cell Lymphoma Patients: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00
  • EE565 Healthcare Consumption and Costs of Hemophilia B in France

    Dec 1, 2023, 00:00
  • HTA289 Optimizing Healthcare Outcomes: Identifying the Conditions for Successful Value-Based Contracts

    Dec 1, 2023, 00:00
  • RWD170 Investigating the Association between Pain Burden and Multimorbidity Among United States Adults with Pain

    Dec 1, 2023, 00:00
  • EE213 Presenting Expected Net Loss Curves to Better Communicate Decision Uncertainty in Cost Effectiveness Analysis

    Dec 1, 2023, 00:00
  • EPH16 Exploring the Effects of the COVID-19 Pandemic on Pneumococcal Disease in Fran A Comprehensive Analysis of Public Health Impact and Economic Burden

    Dec 1, 2023, 00:00
  • EE101 Assessing the Cost-Effectiveness of Introducing Benralizumab in the Treatment of Severe Uncontrolled Eosinophilic Asthma Patients in Prince Sultan Military Medical City (PSMMC) - Kingdom of Saudi Arabia (KSA)

    Dec 1, 2023, 00:00
  • HSD98 Patient Characteristics and Treatment Patterns in Patients with Advanced Psoriasis in Specialty Care Settings in Finland

    Dec 1, 2023, 00:00
  • EE93 Real-World Cost-Effectiveness of Asfotase Alfa for Treatment of Patients with HPP in England

    Dec 1, 2023, 00:00
  • EE645 How Wrong Can It Be? The Impact of Using Inappropriate Adult-Specific Value Set for EQ-5D-Y in Cost-Effectiveness Estimates

    Dec 1, 2023, 00:00
  • EPH145 The Epidemiology of Asthma in Children Between 2004 and 2021 Using Livingstone: An Online, Automated Analytical Platform

    Dec 1, 2023, 00:00
  • HSD43 Survey Research Using PRO Data in Clinical Practi Lessons Learnt from the Nordic Countries

    Dec 1, 2023, 00:00
  • CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic Melanoma

    Dec 1, 2023, 00:00
  • CO186 Characteristics of Psoriasis Patients According to Their Level of Severity Based on a Real-World Ambulatory Medical Database in Fran Preliminary Results

    Dec 1, 2023, 00:00
  • EE616 Cardiometabolic Disease Prevention Policy Models: A Systematic Review

    Dec 1, 2023, 00:00
  • HTA106 What Are the Main Drivers for Decision-Making Regarding the Incorporation of a Healthcare Technology By CONITEC in Brazil? A Study in the Cardiovascular, Oncology, and Respiratory Fields

    Dec 1, 2023, 00:00
  • EPH123 A Machine Augmented Systematic Literature Review: Prevalence of Coinfections in COVID-19 Patients During Early and Late Pandemic Periods

    Dec 1, 2023, 00:00
  • PT19 Analysis of the Access to Medicines for Rare Diseases in Countries from the Balkan Peninsula: A Comparative Analysis

    Dec 1, 2023, 00:00
  • An Intersectional Approach to Quantifying the Impact of Geographic Remoteness and Health Disparities on Quality-Adjusted Life Expectancy: Application to Australia [Editor's Choice]

    Dec 1, 2023, 00:00
  • EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00
  • MSR34 Feasibility of Using Finnish Real-World Data to Build an External Control Arm for the Factor Xia Inhibitor Asundexian Pacific-AF Trial

    Dec 1, 2023, 00:00
  • PCR74 Patient-Centricity in Haemato-Oncology and Oncology Clinical Trials – A Systematic Literature Review on FDA-Approved Treatments From January 2020 to June 2023

    Dec 1, 2023, 00:00
  • EE574 Cost-Effectiveness Analysis of Difelikefalin for Patients with Chronic Kidney Disease-Associated Pruritus (CKD AP) Undergoing Haemodialysis in Italy

    Dec 1, 2023, 00:00
  • EE636 Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Jordan

    Dec 1, 2023, 00:00
  • EE11 Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital

    Dec 1, 2023, 00:00
  • EE456 Cost-Effectiveness of the Development Assistance for Health in Sub-Saharan Africa for HIV, Malaria and Tuberculosis (1995-2018)

    Dec 1, 2023, 00:00
  • EPH162 A Retrospective Analysis of the Public Health Product Tax in Hungary, 2011-2022

    Dec 1, 2023, 00:00
  • EPH202 Current Policy, Clinical and Economic Environment of Eye Care and Vision Health in Bulgaria

    Dec 1, 2023, 00:00
  • EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods

    Dec 1, 2023, 00:00
  • EE760 Using Discrete Choice Experiment to Elicit Treatment Preferences for Acute Allergic Reactions in Sweden: The Case of Patients with Swallowing Problems

    Dec 1, 2023, 00:00
  • EE315 The Budget Impact of Including the Automated Time-Resolved Fluorescence Immunoassay As Point-of-Care Testing on Cardiac Markers in an Emergency Department in China

    Dec 1, 2023, 00:00
  • PCR210 Effectiveness of a Decision Aid for Parents/Caregivers of Children Needing Enteral Support

    Dec 1, 2023, 00:00
  • Real-World Data Information Systems

    Dec 1, 2023, 00:00
  • EE70 Real-World Comparison of Healthcare Resource Utilization and Costs Between Patients with Chronic Lymphocytic Leukemia Treated with First-Line Ibrutinib or Acalabrutinib

    Dec 1, 2023, 00:00
  • CO135 A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of Pharmaceutical Interventions for First-Line (1L) Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00
  • SA33 The Role of Artificial Intelligence in Decoding the Placebo Response - Implications for Clinical Research and Practice

    Dec 1, 2023, 00:00
  • PCR108 Pilot Testing the Hungarian Version of Online Elicitation of Personal Utility Functions Tool for Valuing EQ-5D-5L Health States

    Dec 1, 2023, 00:00
  • EE250 Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review

    Dec 1, 2023, 00:00
  • PCR146 Tuberculosis Patients’ Preferences for Improving Tuberculosis Care in Chitwan District, Nepal: A Discrete Choice Experiment

    Dec 1, 2023, 00:00
  • HSD84 Financial Hardship from Neglected Tropical Diseases: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2023, 00:00
  • HTA262 Cost-Utility Analysis of Influenza Vaccination with a High Dose Quadrivalent Vaccine for the Brazilian Elderly Population in the Private Healthcare Sector

    Dec 1, 2023, 00:00
  • HPR200 Evolution in Public Procurement for Medical Devices in Italy

    Dec 1, 2023, 00:00
  • EE748 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine in Hong Kong

    Dec 1, 2023, 00:00
  • HTA202 Guideline for Costing in Italian Economic Evaluations: A Proposal of the ISPOR Italy Rome Chapter

    Dec 1, 2023, 00:00
  • EPH14 Burden of Respiratory Syncytial Virus Infection in Germany: A Systematic Review

    Dec 1, 2023, 00:00
  • MT64 The Role of Digital Health Technologies in Out-of-Hospital Management of Mental Health Disorders in the UK

    Dec 1, 2023, 00:00
  • EE509 Cost-Effectiveness of Multicancer Early Detection (MCED) With Preferential Detection of Clinically Aggressive Cancers

    Dec 1, 2023, 00:00
  • HPR187 Is the Older Adult Subgroup of the Rare Disease Population Marginalized on Purpose? an Analysis of Equity Issues Encountered By the (OLDER) Rare Disease Population

    Dec 1, 2023, 00:00
  • HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022

    Dec 1, 2023, 00:00
  • CO41 Long-Term Clinical Outcomes in People with Heart Failure with Preserved Ejection Fraction (HFpEF) Treated with Standard Care

    Dec 1, 2023, 00:00
  • Copyright/Subscription

    Dec 1, 2023, 00:00
  • MSR14 Unleashing the Potential of Artificial Intelligence in Genomic Biomarker Testing for Precision Oncology: A Scoping Review

    Dec 1, 2023, 00:00
  • EE490 Analysis of Access and Avalibility of Low Molecular Heparins for the Treatment of COVID-19 during Wartime in Ukraine

    Dec 1, 2023, 00:00
  • HTA52 Time to HTA Assessment Completion By HTA Agency Archetype: Five-Year Review for 20 European Countries

    Dec 1, 2023, 00:00
  • EE413 Economic and Humanistic Burden of Chronic Spontaneous Urticaria: A Systematic Literature Review

    Dec 1, 2023, 00:00
  • EE251 The Impact of Cesarean Birth Complications on Maternal and Infant Health in the World and Turkiye

    Dec 1, 2023, 00:00
  • HSD80 Employees Satisfaction Working at Arta General Hospital of Greece

    Dec 1, 2023, 00:00
  • CO131 Using Non-Randomized Trials to Assess the Clinical Benefit of Systemic Anti-Cancer Treatments: Viable or Not?

    Dec 1, 2023, 00:00
  • HPR133 Analysis of Information Content on the Web Services About Antihypertensive Medicines in Ukraine

    Dec 1, 2023, 00:00
  • MT13 Digging into the Medical Technology HTA Process in Tunisia

    Dec 1, 2023, 00:00
  • EE280 The Lean Assessment Process (LAP) Methodology: An Iterative and Multi-Disciplinary Method for Identifying Clinical Needs, Assessing Technology Acceptance, a Precursor for Early Economic Evaluation and Adoption Strategies

    Dec 1, 2023, 00:00
  • CO146 Language Model-Based Approach for Extracting Comorbidities and Complications in Fabry Disease Clinical Notes

    Dec 1, 2023, 00:00
  • EE551 Study of Costs of Hereditary Angioedema in Routine Clinical Practi Economic Impact of the Disease Burden in Spain

    Dec 1, 2023, 00:00
  • CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review

    Dec 1, 2023, 00:00
  • HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review

    Dec 1, 2023, 00:00
  • MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis

    Dec 1, 2023, 00:00
  • EE224 Out-of-Pocket Health Expenditures of Leukemia and Lymphoma Patients in Portugal

    Dec 1, 2023, 00:00
  • RWD161 Identifying and Characterizing Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Population in Finland

    Dec 1, 2023, 00:00
  • HPR112 International Market Access Strategies for Artificial Intelligence-Based Medical Devices: Can We Standardized the Process to Faster Patient Access?

    Dec 1, 2023, 00:00
  • PT4 Patient-Reported Outcomes (PROs) in German AMNOG-Assessments: Impact of Increasing the Response Threshold to 15 %

    Dec 1, 2023, 00:00
  • PCR179 The Socio-Economic and Health-Related Quality of Life Impact of Myasthenia Gravis (MG) in Greece

    Dec 1, 2023, 00:00
  • EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)

    Dec 1, 2023, 00:00
  • CO68 Gastrointestinal Manifestations and Incontinence Products in the Real World Among Patients with Rett Syndrome in the United States

    Dec 1, 2023, 00:00
  • HTA211 Requirements for Economic Evaluations for Health Technology Assessment Submissions across Different Countries

    Dec 1, 2023, 00:00
  • EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review

    Dec 1, 2023, 00:00
  • EPH149 Prevalence, Burden of Disease, and Treatment Patterns of Vitiligo in Patients Across European Countries

    Dec 1, 2023, 00:00
  • HSD50 Infantile Vaccination Coverage in Brazil From 2016-2022 – Effects of Pandemic Period in Non-COVID-19 Vaccination

    Dec 1, 2023, 00:00
  • EPH260 Rare Diseases and Kidney Stones: Are Stones in Amino Acid Transport Disorders Special?

    Dec 1, 2023, 00:00
  • EE566 Systematic Literature Review for Utility Data in Haemophilia

    Dec 1, 2023, 00:00
  • EE732 Cost-Effectiveness Analysis of Strategies of Autologous Stem-Cell Transplantation and Maintenance Therapy for Transplant-Eligible Multiple Myeloma in China

    Dec 1, 2023, 00:00
  • EPH232 The Disease Burden and Healthcare Resource Utilization of Gram-Negative Multi-Drug Resistant Bacteria

    Dec 1, 2023, 00:00
  • PCR83 Fibrodysplasia Ossificans Progressiva (FOP): The Patient Experience

    Dec 1, 2023, 00:00
  • HTA181 How Can Health Technology Assessment Help in Addressing Drug Repurposing Challenges? A Conceptual Framework

    Dec 1, 2023, 00:00
  • CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia

    Dec 1, 2023, 00:00
  • EE629 The Obesity Burden and Impact of Weight Loss on Saudi Public Payers Using Value of Weight Loss Simulation Model

    Dec 1, 2023, 00:00
  • EPH132 Epidemiology of Breast and Cervical Cancer in Women of the Colombian Caribbean Region During 2018-2021

    Dec 1, 2023, 00:00
  • EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022

    Dec 1, 2023, 00:00
  • EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal

    Dec 1, 2023, 00:00
  • EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

    Dec 1, 2023, 00:00
  • PCR54 Knowledge, Attitudes and Practices of Patients Towards Generics in Greece

    Dec 1, 2023, 00:00
  • EPH103 Estimating the Burden of Vaccine-Preventable Respiratory Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00
  • EE751 Economic Evaluation of Hepatitis B Vaccination Programme in Finland

    Dec 1, 2023, 00:00
  • Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

    Dec 1, 2023, 00:00
  • MSR37 Validation of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM) Among Patients With Knee Osteoarthritis

    Dec 1, 2023, 00:00
  • EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

    Dec 1, 2023, 00:00
  • CO148 Effectiveness of Tocilizumab in Refractory Graves' Orbitopathy in a Real-World Setting

    Dec 1, 2023, 00:00
  • HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe

    Dec 1, 2023, 00:00
  • RWD143 Beyond Accuracy: Automated De-Identification of Large Real-World Clinical Text Datasets

    Dec 1, 2023, 00:00
  • EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe

    Dec 1, 2023, 00:00
  • HTA199 Digital Health Application (DiGA) vs Other Digital Health Technologies (DHT) as Part of Disease Management Programs (DMP)—Assessment Requirements in Germany Diverge Between HTA Authorities

    Dec 1, 2023, 00:00
  • PCR254 Building a COA Strategy in Chronic Rhinosinusitis with or Without Nasal Polyps: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00
  • PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study

    Dec 1, 2023, 00:00
  • «
  • 11
  • 12
  • 13
  • 14 (current)
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • »